Search

Author/Creator Rooney, T.

3. LB0001 Baricitinib, an Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and An Inadequate Response to CDMARD Therapy: Results of the Phase 3 RA-Build Study. (9th June 2015)

Authors:
Dougados, M.; van der Heijde, D.; Chen, Y.-C.; Greenwald, M.; Drescher, E.; Liu, J.; Beattie, S.; de la Torre, I.; Rooney, T.; Schlichting, D.; de Bono, S.; Emery, P.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 74(2015)Supplement 2
Page Start:
79
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. OP0001 BARICITINIB, TOFACITINIB, UPADACITINIB, FILGOTINIB, AND CYTOKINE SIGNALING IN HUMAN LEUKOCYTE SUBPOPULATIONS: AN UPDATED EX-VIVO COMPARISON. (2nd June 2020)

Authors:
Mcinnes, I.; Rocha, G.; Higgs, R. E.; Dairaghi, D.; Wehrman, T.; Wang, E.; Xin, Z.; Ross Terres, J.; Rooney, T.; Taylor, P. C.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 79(2020)Supplement 1
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. OP0029 Baricitinib, An Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-Beacon Study. (9th June 2015)

Authors:
Genovese, M.C.; Kremer, J.; Zamani, O.; Ludivico, C.; Krogulec, M.; Xie, L.; Beattie, S.; Koch, A.E.; Cardillo, T.; Rooney, T.; Macias, W.; Schlichting, D.; Smolen, J.S.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 74(2015)Supplement 2
Page Start:
75
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. SAT0218 Efficacy and safety of baricitinib in mtx-ir patients with rheumatoid arthritis: 52 week results from a phase 3 study (RA-BALANCE). (12th June 2018)

Authors:
Li, Z.; Hu, J.; Bao, C.; Li, X.; Li, X.; Xu, J.; Spindler, A.; Zhang, X.; Xu, J.; Li, Z.; Wang, G.; Sun, J.; Ji, F.; Tao, H.; Zhan, L.; Rooney, T.; Zerbini, C.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 77(2018)Supplement 2
Page Start:
969
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. SAT0253 Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. (12th June 2018)

Authors:
Takeuchi, T.; Genovese, M. C.; Haraoui, B.; Li, Z.; Xie, L.; Klar, R.; Correia, A. P.; Otawa, S.; Lopez-Romero, P.; De La Torre, I.; Rooney, T.; Smolen, J. S.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 77(2018)Supplement 2
Page Start:
988
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. THU0519 OPTIMAL USE OF CONTRAST ENHANCED MRI FOR CLINICAL TRIALS OF INFLAMMATORY DISEASES: RETROSPECTIVE ANALYSIS OF DATA FROM A PHASE IIB STUDY OF BARICITINIB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS. (2nd June 2020)

Authors:
Boesen, M.; Hinton, M.; Gonzalez-Zabaleta, J.; Beattie, S.; Schlichting, D.; Rooney, T.; Kubassova, O.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 79(2020)Supplement 1
Page Start:
498
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗